drugset / Trial / NCT07061717
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a a phase III, randomized, open-label clinical trial comparing endocrine therapy combined with high-dose palbociclib and hydroxychloroquine to endocrine therapy combined with standard-dose palbociclib for hormone receptor-positive and her2-negative advanced breast cancer.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2029-07-01
- Completion
- 2029-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 600 mg | — |
| Comparator | Palbociclib | Small molecule | 125 mg | — |
| Comparator | Palbociclib | Small molecule | 200 mg | — |
| Comparator | Anastrozole | Other / unclassified | 1 mg | — |
| Comparator | Exemestane | Small molecule | 25 mg | — |
| Comparator | Letrozole | Other / unclassified | 2.5 mg | — |